{
  "data": [
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207472,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209817,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210126,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210400,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211542,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212381,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212956,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214079,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217118,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218353,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Pravastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222462,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222463,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Oseltamivir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222464,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222465,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Pantoprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222466,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Nevirapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222467,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Metoprolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222468,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Metformin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222469,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Omeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222470,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222471,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Mexiletine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222472,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222473,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Methylphenidate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222474,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222475,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222476,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Lansoprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222477,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Loratadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222478,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Montelukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222479,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222480,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222481,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222482,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Zanamivir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222483,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Methotrexate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222484,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222485,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Lactulose",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222486,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Ivermectin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222487,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222488,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Stavudine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222489,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Latanoprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222490,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Losartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222491,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Lamivudine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222492,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Paroxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222493,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Lisinopril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222494,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Nitroglycerin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222495,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Olopatadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222496,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Oxcarbazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222497,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222498,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Meloxicam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222499,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Tadalafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222500,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222501,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222502,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222503,
      "ingredient1": "Ketotifen"
    },
    {
      "ingredient2": "Baricitinib",
      "severity": "Major",
      "effect": "Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. The most common serious infections with baricitinib treatment include pneumonia, herpes zoster, and urinary tract infection. Opportunistic infections include tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus. Lymphoma and other malignancies have also been observed with baricitinib use, with or without concomitant immunosuppressants.",
      "management_text": "Close monitoring for the development of infection is recommended if baricitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and baricitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, baricitinib should be interrupted until the infection is controlled.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 38852,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Certolizumab pegol",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61716,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Deferiprone",
      "severity": "Major",
      "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.",
      "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81905,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Rubella virus vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 102090,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Rotavirus vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 110731,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bacillus calmette-guerin substrain tice live antigen",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 151950,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Major",
      "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.",
      "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 151987,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Golimumab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152001,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Samarium (153Sm) lexidronam",
      "severity": "Major",
      "effect": "Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.",
      "management_text": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152047,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Siponimod",
      "severity": "Major",
      "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.",
      "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152050,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Smallpox (Vaccinia) Vaccine, Live",
      "severity": "Major",
      "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152053,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Talimogene laherparepvec",
      "severity": "Major",
      "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152062,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Teriflunomide",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152065,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Thalidomide",
      "severity": "Major",
      "effect": "Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism. The exact mechanism is unknown but likely multifactorial.",
      "management_text": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152066,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Tofacitinib",
      "severity": "Major",
      "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.",
      "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152069,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Typhoid vaccine (live)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152076,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Upadacitinib",
      "severity": "Major",
      "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.",
      "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152077,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Varicella Zoster Vaccine (Recombinant)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152082,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Yellow Fever Vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152086,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Adalimumab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 9324,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cladribine",
      "severity": "Major",
      "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 67583,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Major",
      "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.",
      "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 72504,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Etanercept",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 151980,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Infliximab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 152011,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 6698,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 6867,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 8386,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Clostridium tetani toxoid antigen (formaldehyde inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 8547,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10370,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Amphotericin B",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20338,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Amoxicillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24292,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33970,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Azathioprine",
      "severity": "Moderate",
      "effect": "The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections, particularly in transplant patients. Azathioprine alone may cause dose-related and potentially life-threatening bone marrow suppression, although it is usually reversible when managed promptly. Leucopenia, anemia, thrombocytopenia, and rarely, agranulocytosis, pancytopenia, and aplastic anemia have been reported. Dose-related reductions in numbers of circulating total white cells, granulocytes, and lymphocytes may also occur. Treatment with azathioprine alone or in combination with other immunosuppressants, particularly corticosteroids, has been associated with increased susceptibility to infections including severe or atypical infection and reactivation with varicella zoster virus, hepatitis B, cytomegalovirus, and other infectious agents.",
      "management_text": "Concomitant use of azathioprine with other immunosuppressive or myelosuppressive agents should be avoided whenever possible. Close clinical and laboratory monitoring for hematologic toxicity is advised if coadministration is required. Since azathioprine is considered a slow-acting drug, delayed myelosuppression may occur, and effects may persist even after the drug has been discontinued. Prompt reduction in dosage or temporary withdrawal of azathioprine may be necessary if a persistently low or rapid decline in leucocyte count occurs, or if there is other evidence of bone marrow depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 37351,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Balsalazide",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38627,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bendamustine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40730,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ibandronate",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45832,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Busulfan",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51936,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Canakinumab",
      "severity": "Moderate",
      "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54643,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57584,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefadroxil",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60049,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60071,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefditoren",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60131,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefixime",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60199,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefoxitin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60275,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefpodoxime",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60314,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefprozil",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60343,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefuroxime",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60515,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)",
      "severity": "Moderate",
      "effect": "There are no data regarding the use of live, attenuated cholera vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.",
      "management_text": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64652,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Colistimethate",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73700,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Daunorubicin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 80709,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81639,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Delafloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82682,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Denosumab",
      "severity": "Moderate",
      "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.",
      "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 83193,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Dimethyl fumarate",
      "severity": "Moderate",
      "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.",
      "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 87241,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Diroximel fumarate",
      "severity": "Moderate",
      "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.",
      "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 88084,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Dyphylline",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 95127,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Phenyl salicylate",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 102565,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Benzylpenicillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 106879,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Pentamidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107070,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ticarcillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 113662,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Inotersen",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115221,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Iobenguane (I-131)",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118739,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Isatuximab",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119417,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Human adenovirus e serotype 4 strain cl-68578 antigen",
      "severity": "Moderate",
      "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.",
      "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151945,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bacampicillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151949,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bifidobacterium longum infantis",
      "severity": "Moderate",
      "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151951,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bromfenac",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151952,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Candida albicans",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151953,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefaclor",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151955,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefamandole",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151956,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefonicid",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151958,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefoperazone",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151959,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ceftizoxime",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151960,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefapirin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151962,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefradine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151963,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151965,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cinoxacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151966,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cloxacillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151967,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Coccidioides immitis spherule",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151968,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151970,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Dacarbazine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151972,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151974,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Doripenem",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151975,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Etidronic acid",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151981,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151982,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151983,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151988,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151991,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Gallium nitrate",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151993,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ganciclovir",
      "severity": "Moderate",
      "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.",
      "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151994,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Gatifloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151995,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Gemifloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151997,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Gentamicin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151998,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Givosiran",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151999,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Glucarpidase",
      "severity": "Moderate",
      "effect": "Concomitant administration of glucarpidase may decrease the plasma concentrations and effects of reduced folates and folate antimetabolites, which are potential exogenous substrates of glucarpidase. Conversely, potential substrates of glucarpidase may interfere with its action in the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function by reducing the availability of glucarpidase, a recombinant bacterial enzyme that provides an alternate nonrenal pathway for methotrexate elimination by converting methotrexate to an inactive metabolite and glutamate.",
      "management_text": "On theoretical grounds, caution is advised if glucarpidase is administered in combination with potential substrates such as folate antimetabolites other than methotrexate. With leucovorin, experts recommend administering it two to four hours before or after a dose of glucarpidase. The same precaution may be appropriate with other potential substrates of glucarpidase, although clinical data are currently lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152000,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Hepatitis A Vaccine",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152002,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Hepatitis B Vaccine (Recombinant)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152003,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Human papillomavirus type 11 L1 capsid protein antigen",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152004,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152005,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Idarubicin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152006,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Moderate",
      "effect": "The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.",
      "management_text": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152007,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152008,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152012,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152013,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Phenylbutazone",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152031,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Plazomicin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152033,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Poliovirus type 1 antigen (formaldehyde inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152034,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Polymyxin B",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152035,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Pralatrexate",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152036,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Probenecid",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152037,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Procainamide",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152038,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152039,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Radium Ra 223 dichloride",
      "severity": "Moderate",
      "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.",
      "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152040,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Rilonacept",
      "severity": "Moderate",
      "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152042,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Roflumilast",
      "severity": "Moderate",
      "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.",
      "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152044,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ruxolitinib",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152045,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Salsalate",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152046,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152049,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sipuleucel-T",
      "severity": "Moderate",
      "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.",
      "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152051,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sirolimus",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152052,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sodium phosphate, monobasic (p32)",
      "severity": "Moderate",
      "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.",
      "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152054,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Salicylic acid (sodium)",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152055,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Streptomycin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152056,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Strontium chloride Sr-89",
      "severity": "Moderate",
      "effect": "The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.",
      "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152058,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152059,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152061,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Telavancin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152063,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Temsirolimus",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152064,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Thiotepa",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152067,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Tobramycin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152068,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Topotecan",
      "severity": "Moderate",
      "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.",
      "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152071,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Trichophyton mentagrophytes",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152073,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Tuberculin purified protein derivative",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152074,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ustekinumab",
      "severity": "Moderate",
      "effect": "The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152078,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Valganciclovir",
      "severity": "Moderate",
      "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.",
      "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152081,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Zalcitabine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152087,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Imipenem",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188070,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Zidovudine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 405,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Aldesleukin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13177,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Alefacept",
      "severity": "Moderate",
      "effect": "The use of alefacept with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Patients receiving other immunosuppressive or myelosuppressive agents or phototherapy should not be treated with alefacept because of the possibility of excessive immunosuppression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13584,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Alemtuzumab",
      "severity": "Moderate",
      "effect": "The use of alemtuzumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Alemtuzumab alone may cause severe and prolonged myelosuppression, lymphopenia, and rarely, fatal bone marrow aplasia/hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia. Serious, sometimes fatal opportunistic infections have been reported, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "Caution is advised if alemtuzumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. The manufacturer recommends that single doses of alemtuzumab not exceed 30 mg and cumulative weekly doses not exceed 90 mg, since higher dosages are associated with an increased incidence of pancytopenia. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13859,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17621,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Amikacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20876,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Aminosalicylic acid",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21307,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23584,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ampicillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24652,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Anakinra",
      "severity": "Moderate",
      "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25188,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Aztreonam",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38021,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bacitracin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38158,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bleomycin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45441,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54091,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Capreomycin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55802,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefdinir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60102,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefotaxime",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60223,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 61023,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Chlorambucil",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62156,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Moderate",
      "effect": "Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) have been reported after the administration of chloramphenicol.",
      "management_text": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62416,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cidofovir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65119,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65706,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66222,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66674,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77143,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Phenoxymethylpenicillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 106916,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Piperacillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108278,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sapropterin",
      "severity": "Moderate",
      "effect": "Drugs that affect folate metabolism may reduce the efficacy of sapropterin, which is a synthetic form of tetrahydrobiopterin (BH4). Folate antagonists can decrease tetrahydrobiopterin (BH4) levels by inhibiting the enzyme dihydropteridine reductase.",
      "management_text": "Caution is advised if sapropterin is used in combination with folate antagonists. The potential for diminished pharmacologic effects of sapropterin should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111264,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114922,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Interferon alfa-2b",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 117444,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Carbenicillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151954,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefmetazole",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151957,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cefalotin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151961,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Creatine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151969,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Dicloxacillin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151973,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Efalizumab",
      "severity": "Moderate",
      "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151976,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Enoxacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151977,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Entecavir",
      "severity": "Moderate",
      "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151978,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ertapenem",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151979,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Famciclovir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151984,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151985,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Filgrastim",
      "severity": "Moderate",
      "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.",
      "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151986,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Floxuridine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151989,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151990,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Foscarnet",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151992,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151996,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152009,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152010,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Interferon alfa-2a, Recombinant",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152014,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Piroxicam",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152032,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152043,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sargramostim",
      "severity": "Moderate",
      "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.",
      "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152048,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Streptozocin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152057,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152060,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Tolmetin",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152070,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Triamterene",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152072,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152079,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed. The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins. Use of NSAIDs has been associated with nephropathy manifested as elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. Since pemetrexed is primarily eliminated unchanged by renal excretion, coadministration with NSAIDs may result in delayed and/or decreased clearance.",
      "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function. However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min). These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration. If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152080,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Vinblastine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152083,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152084,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Vitamin E",
      "severity": "Moderate",
      "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.",
      "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152085,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Zoledronic acid",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152088,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Adefovir dipivoxil",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.",
      "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered.  Renal function should be closely monitored during therapy.  Pemetrexed should not be administered to patients whose creatinine clearance is below 45 mL/min.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 241030,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ibritumomab tiuxetan",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 242647,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Telmisartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213413,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213414,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Rosuvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213415,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fluticasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213416,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214036,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214866,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215068,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216879,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217049,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Potassium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217345,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219275,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219782,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Temozolomide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220463,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220583,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221595,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222643,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Salmeterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223054,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223532,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225021,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225245,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225432,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225689,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226788,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Tolterodine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226941,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228588,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229494,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229740,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Rabeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230636,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230763,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230934,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231469,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Clindamycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232230,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Flumazenil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232971,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233018,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233165,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233485,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234456,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234897,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Tiotropium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235435,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Ursodeoxycholic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235745,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Cyanocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194707,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195196,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Pravastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195448,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195594,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196549,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197490,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200030,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201325,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203496,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203750,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205014,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205230,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211185,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212870,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213167,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213355,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213404,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Pregabalin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213405,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213406,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213409,
      "ingredient1": "Pemetrexed"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme. Increased fentanyl concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Conversely, discontinuation of a CYP450 3A4 inhibitor could decrease fentanyl plasma concentrations, decrease opioid efficacy, and possibly even lead to a withdrawal syndrome in patients who had developed physical dependence to fentanyl.",
      "management_text": "Patients receiving fentanyl with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed. This is particularly important when an inhibitor is added after a stable dose of fentanyl has been achieved. Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur, such as dizziness, confusion, fainting, extreme sedation, unresponsiveness, bradycardia, slow or difficult breathing, and shortness of breath.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 2689,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Acalabrutinib",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. Increased acalabrutinib exposure may potentiate the risk of toxicities such as hemorrhage, infection, cytopenias, malignancies, and atrial fibrillation or flutter.",
      "management_text": "The dosage of acalabrutinib should be reduced to 100 mg once daily when coadministered with moderate CYP450 3A4 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 3033,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of alfentanil, which is primarily metabolized by the isoenzyme.",
      "management_text": "Lower dosages of alfentanil may be required when used in combination with potent and moderate CYP450 3A4 inhibitors (e.g., azole antifungal agents, protease inhibitors, ketolide and certain macrolide antibiotics, aprepitant, diltiazem, dalfopristin-quinupristin, delavirdine, imatinib, nefazodone, verapamil). Patients should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary. Recovery time from alfentanil anesthesia may be prolonged in some cases.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 14579,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Major",
      "effect": "Amiodarone and diltiazem or verapamil may have additive pharmacodynamic effects when administered concurrently. Sinus arrest, reduced myocardial contractility, and hypotension could result.",
      "management_text": "The patient's hemodynamic and electrocardiographic status should be closely monitored, especially during amiodarone loading.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21890,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme. Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.",
      "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine). A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 27391,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Betrixaban",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the plasma concentrations of betrixaban, which is a substrate of the efflux transporter. In the Acute Medically Ill Prevention with Extended Duration Betrixaban (APEX) Study, use of betrixaban at a 50% dosage reduction in combination with P-gp inhibitors or in the presence of severe renal impairment was associated with increased relative risks of bleeding, including major bleeding, compared to treatment with enoxaparin.",
      "management_text": "When used with P-gp inhibitors, the recommended dosage of betrixaban is an initial single dose of 80 mg followed by 40 mg once daily. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 42973,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of bosutinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of bosutinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of bosutinib during and for 2 weeks after treatment with itraconazole. If use of a potent or moderate CYP450 3A4 inhibitor is required, an interruption or a dosage reduction of bosutinib therapy should be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 46827,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Brexpiprazole",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these isoenzymes.",
      "management_text": "The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors. The brexpiprazole dosage should be increased to the original level if these agents are discontinued. It is advisable to monitor patients for clinical response.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 47963,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Brigatinib",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme.",
      "management_text": "Concomitant use of moderate CYP450 3A4 inhibitors should generally be avoided during therapy with brigatinib. If coadministration is required, the brigatinib dose should be reduced by approximately 40% (i.e., from 180 mg to 120 mg, 120 mg to 90 mg, or from 90 mg to 60 mg). There are authorities (AU and UK) that state that no dose adjustment is required, however, patients should be closely monitored. Patients should be monitored for increased brigatinib adverse reactions such as nausea, vomiting, diarrhea, hypertension, bradycardia, hyperglycaemia, visual disturbances, lymphopenia, anemia, and elevations in pancreatic enzymes and creatine phosphokinase. If a dose adjustment is made, the brigatinib dose that was tolerated previously may be resumed following discontinuation of the CYP450 3A4 inhibitor.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 48378,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Major",
      "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.",
      "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 60015,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Major",
      "effect": "Coadministration of ceritinib with other drugs that can slow the heart rate such as beta-blockers, calcium channel blockers, digitalis, and clonidine may increase the risk of bradycardia, which can lead to heart block and QT prolongation.",
      "management_text": "Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible. All patients treated with ceritinib should have their heart rate and blood pressure monitored regularly. Consult the product labeling for dosage adjustment and management recommendations if symptomatic or life-threatening bradycardia occurs. Patients should be advised to notify their doctor if they experience irregular heartbeat, slow pulse, dizziness, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61517,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cilostazol",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.",
      "management_text": "A 50% dosage reduction of cilostazol (i.e., 50 mg twice a day) should be considered when used with potent or moderate CYP450 3A4 and/or 2C19 inhibitors. Close clinical and laboratory monitoring is advised whenever the inhibitor is added to or withdrawn from therapy, and the cilostazol dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 65495,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cobimetinib",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. The risk and/or severity of adverse effects such as diarrhea, nausea, vomiting, stomatitis, hemorrhage, cardiomyopathy, rash, photosensitivity, retinopathy, retinal vein occlusion, liver enzyme abnormalities, and rhabdomyolysis may be increased.",
      "management_text": "Concomitant use of cobimetinib with moderate CYP450 3A4 inhibitors should be avoided whenever possible. If short-term (14 days or less) use of a moderate CYP450 3A4 inhibitor is required during treatment with cobimetinib 60 mg once daily, the manufacturer suggests reducing the cobimetinib dose to 20 mg. Following discontinuation of the moderate CYP450 3A4 inhibitor, the previous dose of 60 mg may be resumed. An alternative to the moderate CYP450 3A4 inhibitor should be used in patients who are already taking a reduced dose of cobimetinib (40 or 20 mg daily).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 73135,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Colchicine",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the isoenzyme. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur.",
      "management_text": "Caution is advised if colchicine is prescribed in combination with moderate CYP450 3A4 inhibitors. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with moderate CYP450 3A4 inhibitors or within 14 days of using them. For the treatment of acute gout flares, the adjusted dosage recommended is 1.2 mg for one dose. Administration should not be repeated for at least three days. For the prophylaxis of gout flares, the adjusted dosage should be 0.3 mg twice a day (or 0.6 mg once a day) if the original regimen was 0.6 mg twice a day, and 0.3 mg once a day if the original regimen was 0.6 once a day. For the treatment of familial Mediterranean fever, the maximum dosage of colchicine is 1.2 mg/day (may be given as 0.6 mg twice a day) when used in the presence of moderate CYP450 3A4 inhibitors. Other significant inhibitors of CYP450 3A4 include amiodarone, dronedarone, imatinib, posaconazole, and quinupristin-dalfopristin, although the extent to which they may interact with colchicine is unknown. A similar dosage adjustment may be required. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paresthesia, and numbness.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 73536,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.",
      "management_text": "The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of deflazacort and CYP450 3A inhibitors unless the benefit outweighs the risk, in which case patients should be monitored for systemic corticosteroid side effects.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75305,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma concentrations of docetaxel, which is a substrate of both CYP450 3A4 and P-gp.",
      "management_text": "Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided. Some authorities recommend avoiding concomitant use of docetaxel during and for 2 weeks after treatment with itraconazole. If concomitant use is required, a reduced dosage of docetaxel should be considered. Based on extrapolation from the pharmacokinetic study in 7 cancer patients, a 50% reduction in the docetaxel dose may be reasonable. Patients should be closely monitored for the development of docetaxel toxicity such as myelosuppression, stomatitis, neurotoxicity (e.g., paraesthesia, dysesthesia, pain), myalgia, asthenia, fluid retention, nausea, vomiting, and diarrhea.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75318,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Major",
      "effect": "Dolasetron has been shown to cause dose-dependent prolongation of the PR and QRS intervals. There have been reports of second- and third-degree atrioventricular block, cardiac arrest, and serious ventricular arrhythmias including fatalities in both adult and pediatric patients.",
      "management_text": "Caution is advised if dolasetron is used concomitantly with other agents that prolong the PR or QRS interval, especially in the elderly and patients with known risk factors. An ECG should be obtained in these patients before initiating dolasetron and periodically during treatment. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat. Dolasetron should be avoided in patients with complete heart block or at risk for complete heart block, unless they have an implanted pacemaker.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75320,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Edoxaban",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of edoxaban, which is a substrate of the efflux transporter.",
      "management_text": "When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil. This dosage recommendation is based on data from a clinical study, the Hokusai VTE study, and is limited to use with the specific P-gp inhibitors mentioned.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75335,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Eliglustat",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.",
      "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75338,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Encorafenib",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies.",
      "management_text": "Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-half of the dose used prior to addition of the moderate CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75341,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.",
      "management_text": "Concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the dosage of entrectinib should be reduced to 100 mg once daily for adults and pediatrics patients (12 years and older) with a body surface area (BSA) greater than 1.5 m2. Following discontinuation, and after an appropriate washout period of the CYP450 3A4 inhibitor (i.e., 3 to 5 half-lives), the entrectinib dosage taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75344,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Eplerenone",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75346,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Everolimus",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycaemia, and hyperlipidemia may be increased.",
      "management_text": "Blood trough levels should be closely monitored, and the dosage adjusted accordingly during concomitant administration and after discontinuation of moderate CYP450 3A4 and P-glycoprotein inhibitors. The manufacturer's drug product labeling should be consulted for specific recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75361,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Major",
      "effect": "The risk of severe bradycardia and atrioventricular (AV) block may be increased during initiation of fingolimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis. Fingolimod can cause a decrease in heart rate during initiation of therapy that is apparent within an hour of the first dose and maximal at approximately 6 hours postdose in most cases, but occasionally up to 20 hours after the first dose.",
      "management_text": "Fingolimod has not been adequately studied in patients receiving beta-blockers, calcium channel blockers, or digitalis. The possibility of switching to alternative agents that do not slow heart rate or AV conduction should be evaluated by the physician before initiating fingolimod. In patients who cannot switch, overnight continuous ECG monitoring after the first dose is recommended in accordance with the product labeling. The same precautions are applicable if, after the first month of treatment, fingolimod is discontinued for more than two weeks and then restarted, since the effects on heart rate and AV conduction may recur on reintroduction of fingolimod. Within the first 2 weeks of treatment, first-dose procedures are also recommended after interruption of one day or more; during week 3 and 4 of treatment, first-dose procedures are recommended after treatment interruption of more than 7 days. The first dose should always be administered in a setting where resources to appropriately manage symptomatic bradycardia are available.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75367,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Major",
      "effect": "Limited data indicate that verapamil and flecainide may have additive cardiodepressant effects.Diltiazem may interact with flecainide in a similar manner, although no data are available.",
      "management_text": "The patient should be monitored closely when either drug is added to the regimen or when dose increases are made.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75368,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Major",
      "effect": "Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19. High plasma levels of flibanserin may increase the risk of severe hypotension, syncope, and central nervous system depression.",
      "management_text": "Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated. When initiating flibanserin following treatment with a moderate or potent CYP450 3A4 inhibitor, the manufacturer recommends waiting until 2 weeks after the last dose of CYP450 3A4 inhibitor. Conversely, if a moderate or potent CYP450 3A4 inhibitor is required during flibanserin therapy, flibanserin should be discontinued at least 2 days before starting the CYP450 3A4 inhibitor.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75369,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme. The risk of adverse reactions such as hypotension, bradycardia, and sedation may increase.",
      "management_text": "Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors. For extended-release guanfacine, the manufacturers recommend reducing the dosage to half the recommended level during concomitant use . Further dosage adjustments may be required based on patient tolerance and response.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75396,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Halofantrine",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine. Halofantrine has been associated with QT interval prolongation, ventricular arrhythmias, and sudden death, even at recommended dosages.",
      "management_text": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75397,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ibrutinib",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "The dosage of ibrutinib should be adjusted according to the indication in the product labeling whenever it is used in combination with a moderate CYP450 3A4 inhibitor such as amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir, diltiazem, dronedarone, erythromycin, fluconazole, fosamprenavir, fosaprepitant, imatinib, or verapamil. All patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75403,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Major",
      "effect": "Itraconazole exhibits a dose-related negative inotropic effect which may be additive to those of calcium channel blockers (CCBs). Theoretically, coadministration may potentiate the risk of ventricular dysfunction, congestive heart failure, and peripheral and pulmonary edema, particularly in patients with preexisting risk factors (e.g., a history of congestive heart failure; cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disorder; edematous disorders such as renal failure). In addition, both itraconazole and its major metabolite, hydroxyitraconazole, inhibit CYP450 3A4 metabolism and may interfere with the clearance of certain CCBs like the dihydropyridines (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine, nisoldipine), diltiazem, and verapamil. Significant increases of severalfold in felodipine and nifedipine plasma concentrations have been observed during coadministration with itraconazole, and there have been case reports of leg and ankle edema in patients treated with various itraconazole-dihydropyridine combinations. Itraconazole alone has also been associated with postmarketing reports of congestive heart failure, peripheral edema, and pulmonary edema in patients treated for onychomycosis and/or systemic fungal infections.",
      "management_text": "Caution is advised if itraconazole must be used concomitantly with CCBs. Close monitoring of clinical response and tolerance is recommended, and patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis. Appropriate dosage adjustment of the CCB may be necessary when used with itraconazole. Some authorities consider concomitant administration of bepridil and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75422,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ivabradine",
      "severity": "Major",
      "effect": "Coadministration with diltiazem or verapamil may significantly increase the plasma concentrations of ivabradine and increase the risk of excessive bradycardia or other conduction disturbances. The mechanism likely involves both inhibition of the CYP450 3A4-mediated metabolism of ivabradine by the calcium channel blockers as well as additive effects of these agents on heart rate, as they all exhibit negative chronotropic properties.",
      "management_text": "Concomitant use of ivabradine with diltiazem or verapamil should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75423,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.",
      "management_text": "Please consult manufacturer's product labeling for complete dosing information. For ivacaftor - The frequency of dosing should be reduced to 1 tablet or packet once a day when coadministered with moderate CYP450 3A4 inhibitors. Patients should continue to receive the same tablet or oral granule packet strength, but instead of dosing twice a day, the frequency should be reduced to once a day.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75424,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zanubrutinib",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme. Increased zanubrutinib exposure may potentiate the risk of toxicities such as hemorrhage, infection, cytopenias, malignancies, and atrial fibrillation or flutter.",
      "management_text": "The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg twice daily when coadministered with moderate CYP450 3A4 inhibitors. Patients should be closely monitored for development of zanubrutinib-related toxicities, and further dosage adjustments made or treatment withheld as needed in accordance with the product labeling. Following discontinuation of the CYP450 3A4 inhibitor, the previous dosage of zanubrutinib should be resumed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75685,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Betaxolol (ophthalmic)",
      "severity": "Major",
      "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.",
      "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 42359,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Major",
      "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.",
      "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 45209,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Butorphanol",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of butorphanol according to the product labeling. Increased butorphanol concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Conversely, discontinuation of a CYP450 3A4 inhibitor could decrease butorphanol plasma concentrations, decrease opioid efficacy, and possibly even lead to a withdrawal syndrome in patients who had developed physical dependence to butorphanol.",
      "management_text": "Patients receiving butorphanol with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed. Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur, such as dizziness, confusion, fainting, extreme sedation, unresponsiveness, bradycardia, slow or difficult breathing, and shortness of breath. When discontinuing CYP450 3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 52622,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Major",
      "effect": "Coadministration with diltiazem or verapamil may significantly increase the plasma concentrations of carbamazepine. The proposed mechanism is inhibition of carbamazepine metabolism via CYP450 3A4. There have been case reports of carbamazepine toxicity associated with the use of both calcium channel blockers (CCBs), which is consistent with their status as moderate CYP450 3A4 inhibitors. The onset is usually within 2 to 4 days after initiation of the CCB, and a reduction in carbamazepine dosage by 50% to 60% or discontinuation of the CCB is often required.",
      "management_text": "Caution is advised during concomitant use of carbamazepine with diltiazem or verapamil. Serum carbamazepine levels and pharmacologic response should be monitored more closely following the initiation or discontinuation of CCB therapy, and the carbamazepine dosage adjusted as necessary. Some clinicians recommend empirically reducing the carbamazepine dosage by 50% upon initiation of the CCB. Patients should be advised to contact their physician if they experience potential signs and symptoms of carbamazepine toxicity such as headache, nausea, vomiting, dizziness, confusion, slurred speech, nystagmus, visual disturbances, tremors, and ataxia. If carbamazepine is added to existing diltiazem or verapamil therapy, patients should be monitored for potentially reduced blood pressure and cardiac effects.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 56734,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Carteolol (ophthalmic)",
      "severity": "Major",
      "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.",
      "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 59620,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cisapride",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cisapride, which is primarily metabolized by the isoenzyme. High plasma levels of cisapride have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death.",
      "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, protease inhibitors, certain macrolide antibiotics, nefazodone) is considered contraindicated. Use with other agents known to inhibit CYP450 3A4 should generally be avoided if possible.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75288,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Disopyramide",
      "severity": "Major",
      "effect": "Concomitant use of disopyramide with other drugs that have negative inotropic effects such as verapamil may cause profound hypotension, syncope, bradycardia, asystole and heart failure, particularly in patients with conduction defects. Additionally, verapamil is a moderate CYP450 3A4 inhibitor and may interfere with the clearance of disopyramide. Increased exposure to disopyramide may potentiate the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "In general, concomitant use of disopyramide with verapamil should be avoided except in carefully selected patients (e.g., patients with symptomatic obstructive hypertrophic cardiomyopathy refractory to verapamil alone) who are under close medical supervision. The prescribing information for disopyramide and verapamil both recommend that disopyramide not be administered within 48 hours before or 24 hours after verapamil administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75317,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of organic cation transporter 2 (OCT-2) may increase the plasma concentrations of dofetilide, which is primarily eliminated by glomerular filtration and active tubular secretion via OCT-2, with minor contribution from CYP450 3A4-mediated metabolism.",
      "management_text": "Given the risk of concentration-dependent QT prolongation, concomitant use of dofetilide with OCT-2 inhibitors is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75319,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme. The use of erythromycin has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes. In addition, erythromycin may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.",
      "management_text": "Concomitant use of erythromycin with potent CYP450 3A4 inhibitors should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75353,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Esmolol",
      "severity": "Major",
      "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.",
      "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75355,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bromocriptine",
      "severity": "Major",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of bromocriptine.  Orally administered bromocriptine is extensively metabolized in the gastrointestinal tract and liver by CYP450 3A4, with approximately 93% of the absorbed dose undergoing first-pass metabolism and only the remaining 7% reaching systemic circulation.  As such, inhibitors of CYP450 3A4 may markedly reduce the metabolic clearance of bromocriptine.",
      "management_text": "Caution and close monitoring for development of adverse effects are advisable during coadministration of bromocriptine with moderate CYP450 3A4 inhibitors.  Bromocriptine dosage may need to be reduced to avoid toxicity.  The prescribing information for Cycloset, a bromocriptine product indicated for use in adults with type 2 diabetes mellitus to improve glycemic control, recommends limiting the dose to 1.6 mg daily during concomitant use of a moderate CYP450 3A4 inhibitor.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 260423,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Abametapir (topical)",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations. The proposed mechanism is high and prolonged systemic exposure to the metabolite abametapir carboxyl, which has been shown to be an in vitro inhibitor of CYP450 3A4, CYP450 2B6, and CYP450 1A2.",
      "management_text": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion. If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 867,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Abemaciclib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which are substrates of the isoenzyme.",
      "management_text": "Caution is advised when abemaciclib is used with CYP450 3A4 inhibitors. Dosage adjustments for abemaciclib in 50 mg decrements may be necessary and should be done in accordance with the product labeling. Patients should be monitored for potentially increased adverse effects such as nausea, vomiting, diarrhea, stomatitis, venous thromboembolism, hepatotoxicity, anemia, neutropenia, and thrombocytopenia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1285,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10464,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Afatinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter.",
      "management_text": "Caution is advised if afatinib is used in combination with P-gp inhibitors. Patients should be monitored for potentially increased adverse effects such as diarrhea, which may lead to dehydration with or without renal impairment; cutaneous reactions including rash, erythema, and bullous, blistering, or exfoliating lesions; interstitial lung disease such as lung infiltration, pneumonitis, acute respiratory distress syndrome, and allergic alveolitis; hepatotoxicity, which may be life-threatening or fatal; keratitis characterized by acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, red eye, and/or ulceration; and left ventricular dysfunction. The manufacturer recommends reducing the daily dose of afatinib by 10 mg if not tolerated. The previous dose may be resumed after discontinuation of the P-gp inhibitor as tolerated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10643,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.",
      "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11480,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Verapamil may increase the blood concentrations and intoxicating effects of ethanol. The exact mechanism of interaction is unknown but may involve verapamil inhibition of ethanol metabolism.",
      "management_text": "Patients treated with verapamil should be counseled to avoid alcohol consumption.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12856,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alectinib",
      "severity": "Moderate",
      "effect": "Coadministration of alectinib with other agents that can slow the heart rate may increase the risk of bradycardia.",
      "management_text": "Caution is advised when alectinib is prescribed with other drugs that can cause bradycardia (e.g., beta-blockers; calcium channel blockers; digitalis; dolasetron; flecainide; ivabradine; lacosamide; mefloquine; moricizine; propafenone; quinine; succinylcholine; sunitinib; thalidomide; anticholinesterase or cholinergic agents; protease inhibitors such as atazanavir, lopinavir/ritonavir, and saquinavir/ritonavir). Heart rate and blood pressure should be monitored regularly, and patients should be counseled to seek medical attention if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13383,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Aliskiren",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein may increase the plasma concentrations and pharmacologic effects of aliskiren, which is a substrate of both the isoenzyme and efflux transporter. According to the product labeling, plasma levels of aliskiren were increased approximately 80% by the potent CYP450 3A4 and moderate P-gp inhibitor ketoconazole at a dosage of 200 mg twice daily.",
      "management_text": "Pharmacologic response to aliskiren should be monitored more closely whenever a CYP450 3A4 and/or P-gp inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted if necessary. Patients should be advised to notify their physician if they experience excessive adverse effects of aliskiren such as dizziness, lightheadedness, diarrhea, abdominal pain, and gastroesophageal reflux.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16948,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alpelisib",
      "severity": "Moderate",
      "effect": "Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9.",
      "management_text": "Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19018,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amifostine",
      "severity": "Moderate",
      "effect": "Concomitant use with hypotensive agents may increase the risk and severity of hypotension associated with amifostine. Hypotension has been reported frequently in patients treated with amifostine. It is usually transient (lasting from 5 to 15 minutes) and closely associated with amifostine administration, but may persist or become evident hours after administration.",
      "management_text": "If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20768,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amisulpride",
      "severity": "Moderate",
      "effect": "Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. The concomitant use of amisulpride with agents that can cause bradycardia may theoretically potentiate the risk of QT interval prolongation and torsade de pointes arrhythmia.",
      "management_text": "Caution and clinical monitoring (e.g., electrocardiogram, serum electrolytes) are recommended if amisulpride is used in combination with other drugs that can cause bradycardia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22217,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "Some barbiturates may significantly decrease serum verapamil concentrations and half-life, especially with oral dosage forms. The mechanism is induction of CYP450 3A4 first-pass metabolism of verapamil.",
      "management_text": "Close observation for reduced verapamil effect is recommended if these drugs must be used together. Dose adjustments may be required. Patients should also be monitored for verapamil toxicity after the barbiturate is discontinued.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24261,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 28542,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Moderate",
      "effect": "Several case reports have suggested that verapamil and aspirin may have synergistic antiplatelet effects. The mechanism of this interaction has not been fully elucidated. Also, one study of five patients has suggested that aspirin may reverse the antihypertensive effect of verapamil. The mechanism may be related to antagonism of the effect of verapamil on prostacyclin. Diltiazem has been shown to interact with aspirin in a similar manner.",
      "management_text": "Close observation for prolonged bleeding time and reduced antihypertensive effect is recommended if these drugs must be used together. Patients should be advised to notify their physician if they experience unusual bleeding, bruising, or petechiae. Aspirin should be discontinued if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34050,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fluticasone (nasal)",
      "severity": "Moderate",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation. Fluticasone undergoes extensive first-pass and systemic metabolism via CYP450 3A4, thus inhibition of the isoenzyme may significantly increase systemic bioavailability of the drug. However, the extent of interaction may depend on the route of fluticasone administration and the specific formulation.",
      "management_text": "Monitor for signs and symptoms of hypercorticism if intranasal or orally inhaled fluticasone is coadministered with a moderate inhibitor of CYP450 3A4. Signs and symptoms of hypercorticism include acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma). Systemic glucocorticoids may be necessary until adrenal function recovers.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 37482,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.",
      "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39524,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bictegravir",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir. According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.",
      "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors. Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43869,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Binimetinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib. The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.",
      "management_text": "Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors. Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44020,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Calcium Phosphate",
      "severity": "Moderate",
      "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.",
      "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45741,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Brentuximab vedotin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.",
      "management_text": "Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 47300,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.",
      "management_text": "The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50295,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of buprenorphine, which is partially metabolized (approximately 30%) by the isoenzyme.",
      "management_text": "Caution is advised if buprenorphine is prescribed with CYP450 3A4 inhibitors. Induction with buprenorphine should begin at a reduced dosage, and dosage escalation should occur more slowly to allow for assessment of opiate effects and development of patient tolerance. In patients who are already stabilized on buprenorphine, pharmacologic response and vital signs should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51435,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cabazitaxel",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised if cabazitaxel is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to cabazitaxel should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the cabazitaxel dosage adjusted as necessary. Regular monitoring of peripheral blood counts between treatment cycles is recommended, and patients should be advised to contact their physician if they experience potential signs and symptoms of cabazitaxel toxicity such as infection, fever, chills, diarrhea, unusual bruising or bleeding, and burning, tingling, or numbness in the hands and feet.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52861,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cabozantinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme.",
      "management_text": "Caution is advised if cabozantinib is used with moderate CYP450 3A4 inhibitors. Patients should be monitored for potentially increased side effects such as nausea, vomiting, diarrhea, anorexia, weight loss, stomatitis, gastrointestinal perforations and fistulas, palmar-plantar erythrodysesthesia syndrome, hemorrhage, wound complications, hypertension, neutropenia, and thrombocytopenia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53356,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Canagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54483,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Capmatinib",
      "severity": "Moderate",
      "effect": "Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters, such as digoxin and rosuvastatin. The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of intestinal P-gp and/or BCRP efflux transport proteins.",
      "management_text": "Coadministration of capmatinib with drugs that are substrates of P-gp and/or BCRP should generally be avoided. However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55729,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cariprazine",
      "severity": "Moderate",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine (DDCAR), both of which are primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when cariprazine is prescribed with moderate CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as extrapyramidal symptoms, cognitive and motor impairment, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leukopenia, neutropenia, seizures and dysphagia, and the dosage of cariprazine adjusted as necessary in accordance with the product labeling.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58789,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Moderate",
      "effect": "According to a single case report, when ceftriaxone and clindamycin were added to the regimen of a patient who was receiving a stable dosage of verapamil and other medications, acute verapamil toxicity resulted. The patient developed complete heart block. The mechanism is unknown and causality was not clearly determined. The purported mechanism (displacement of verapamil from protein binding sites) has been disputed.",
      "management_text": "Until more information is available, patients should be monitored for verapamil toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60481,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64987,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Moderate",
      "effect": "Coadministration with certain macrolide antibiotics may increase the plasma concentrations and pharmacologic effects of verapamil. The proposed mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for hepatic first-pass and systemic metabolic clearance of verapamil. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. Azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4. Clinically, the interaction is supported by isolated case reports of elderly patients stabilized on verapamil and other medications who developed symptoms of verapamil toxicity (e.g., hypotension, bradycardia, atrioventricular block) within 2 to 7 days after initiation of erythromycin or clarithromycin therapy. One of the patients also had QT interval prolongation, which may be induced by elevated levels of erythromycin secondary to inhibition of intestinal P-glycoprotein and CYP450 3A4 by verapamil. The interaction was also suspected in a 53-year-old woman who was started on verapamil and clarithromycin concurrently and developed bradycardia, dizziness, hypotension and fainting after 24 hours. In all cases, discontinuation or dosage reduction of verapamil in addition to supportive care led to resolution of symptoms.",
      "management_text": "Caution is advised if verapamil must be used with clarithromycin, erythromycin or troleandomycin, particularly in susceptible patients such as the elderly or debilitated. Cardiac function and pharmacologic response to verapamil should be monitored more closely whenever the macrolide antibiotic is added to or withdrawn from therapy in patients stabilized on their verapamil regimen, and the dosage adjusted as necessary. Azithromycin and dirithromycin may be safer alternatives during therapy with verapamil.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 68148,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clindamycin",
      "severity": "Moderate",
      "effect": "According to a single case report, when ceftriaxone and clindamycin were added to the regimen of a patient who was receiving a stable dosage of verapamil and other medications, acute verapamil toxicity resulted. The patient developed complete heart block. The mechanism is unknown and causality was not clearly determined. The purported mechanism (displacement of verapamil from protein binding sites) has been disputed.",
      "management_text": "Until more information is available, patients should be monitored for verapamil toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 69495,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Concurrent administration of verapamil may increase tricyclic antidepressant (TCA) serum concentrations. The mechanism appears to be inhibition of CYP450 metabolism. Pharmacologic and toxic effects of TCAs may be increased.",
      "management_text": "Close monitoring for clinical response and tolerance is recommended whenever verapamil is added to or discontinued from an antidepressant regimen. Patients should be advised to notify their physician if they experience excessive antidepressant effects such as dry mouth, blurry vision, irregular or fast heartbeat, constipation, urinary retention, dizziness, or orthostatic hypotension. Dose adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70990,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cobicistat",
      "severity": "Moderate",
      "effect": "Coadministration with cobicistat may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 or 2D6 isoenzymes and/or P-glycoprotein (P-gp) efflux transporter.",
      "management_text": "Caution is advised if cobicistat is used concomitantly with medications that undergo metabolism primarily by CYP450 3A4 and/or 2D6 or are substrates of P-glycoprotein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cobicistat is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 72932,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Conivaptan",
      "severity": "Moderate",
      "effect": "Coadministration with conivaptan may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by conivaptan.",
      "management_text": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever conivaptan is added to or withdrawn from therapy, or the combination avoided altogether.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74515,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iothalamic acid",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74637,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Corticotropin",
      "severity": "Moderate",
      "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.",
      "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74843,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Aminophylline",
      "severity": "Moderate",
      "effect": "Verapamil may increase theophylline serum levels, theophylline effect, and risk of toxicity. The mechanism is inhibition of CYP450 hepatic metabolism by verapamil. Other hepatically metabolized methylxanthines may also be affected. Cigarette smokers appear to have a greater risk of developing theophylline toxicity from this combination.",
      "management_text": "Clinical monitoring of patient response and tolerance and serum theophylline levels is recommended. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physicians. Theophylline dosage should be reduced as appropriate. Isradipine and nifedipine appear to have minimal effects on theophylline pharmacokinetics.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75267,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Moderate",
      "effect": "Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.",
      "management_text": "Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75269,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bismuth subsalicylate",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75273,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Boceprevir",
      "severity": "Moderate",
      "effect": "Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most calcium channel blockers.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with boceprevir or telaprevir. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75274,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bromfenac",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75275,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Calcium carbonate",
      "severity": "Moderate",
      "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.",
      "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75277,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Calcium glubionate anhydrous",
      "severity": "Moderate",
      "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.",
      "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75280,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Calcium glycerophosphate",
      "severity": "Moderate",
      "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.",
      "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75283,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Copanlisib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "Caution is advised when copanlisib is used with CYP450 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as nausea, vomiting, diarrhea, stomatitis, hyperglycemia, hypertension, noninfectious pneumonitis, cutaneous reactions (e.g., exfoliative dermatitis, maculopapular rash), anemia, neutropenia, thrombocytopenia, and infections. Dosage adjustments for copanlisib may be necessary and should be done in accordance with the product labeling.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75290,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Moderate",
      "effect": "Crizotinib can cause bradycardia and may have additive effects with other drugs that also slow the heart rate.",
      "management_text": "Concomitant use of crizotinib with other agents known to cause bradycardia such as beta-blockers, calcium channel blockers, cholinesterase inhibitors, clonidine, and digoxin should generally be avoided whenever possible. Otherwise, heart rate and blood pressure should be monitored closely. If Grade 2 or 3 symptomatic bradycardia occurs, crizotinib should be withheld, the use of concomitant medications re-evaluated, and the dosage of crizotinib adjusted accordingly. Crizotinib should be permanently discontinued for Grade 4 bradycardia. In patients who develop Grade 4 bradycardia associated with concomitant medications known to cause bradycardia or hypotension, crizotinib should be withheld until Grade 1 or less, and if concomitant medications can be discontinued, crizotinib may be restarted at 250 mg once daily with frequent monitoring.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75291,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Moderate",
      "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.",
      "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75293,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Daclatasvir",
      "severity": "Moderate",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75294,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dalfampridine",
      "severity": "Moderate",
      "effect": "The concomitant use of dalfampridine with drugs that are inhibitors of organic cation transporter 2 (OCT2) may theoretically reduce its renal clearance. Dalfampridine is primarily eliminated through renal excretion, approximately 60% of which is via active secretion by OCT2. Elevated levels of dalfampridine may increase the risk of CNS excitation and seizures.",
      "management_text": "Caution is advised when dalfampridine is used with OCT2 inhibitors. The benefit of concomitant use should be weighed against the potential risk of seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75295,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Moderate",
      "effect": "Several case reports have suggested that the combination of verapamil and dantrolene may cause hyperkalemia and myocardial depression. The mechanism is unknown. Causality was not definitely established due to the presence of other drugs. Diltiazem may also interact.",
      "management_text": "The manufacturer recommends that concomitant administration should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75296,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dapagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75297,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Darunavir",
      "severity": "Moderate",
      "effect": "Coadministration with darunavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by darunavir.",
      "management_text": "Caution is advised if darunavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever darunavir is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75300,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised if dasatinib is used in combination with moderate CYP450 3A4 inhibitors. Close monitoring for toxicity (e.g., myelosuppression, bleeding complications, fluid retention) is recommended, and the dasatinib dosage adjusted as necessary. Patients should also be monitored for altered efficacy and safety of the concomitant administered drug.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75301,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Daunorubicin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.",
      "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75302,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Moderate",
      "effect": "Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.",
      "management_text": "Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75304,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Moderate",
      "effect": "Coadministration with delavirdine may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves delavirdine inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most calcium channel blockers.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with delavirdine. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75306,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Deserpidine",
      "severity": "Moderate",
      "effect": "The hypotensive effects of some calcium channel blockers and alpha-adrenergic blockers may be additive. The proposed mechanism is additive vasodilatory effects and inhibition of CYP450 hepatic metabolism of some alpha blockers by certain calcium channel blockers.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75307,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Desflurane",
      "severity": "Moderate",
      "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.",
      "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75308,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Desipramine",
      "severity": "Moderate",
      "effect": "Concurrent administration of verapamil may increase tricyclic antidepressant (TCA) serum concentrations. The mechanism appears to be inhibition of CYP450 metabolism. Pharmacologic and toxic effects of TCAs may be increased.",
      "management_text": "Close monitoring for clinical response and tolerance is recommended whenever verapamil is added to or discontinued from an antidepressant regimen. Patients should be advised to notify their physician if they experience excessive antidepressant effects such as dry mouth, blurry vision, irregular or fast heartbeat, constipation, urinary retention, dizziness, or orthostatic hypotension. Dose adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75309,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75312,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Digitoxin",
      "severity": "Moderate",
      "effect": "Verapamil may increase serum digitoxin concentrations. The mechanism is unknown, but may be decreased extrarenal elimination of digitoxin.",
      "management_text": "If digitoxin and verapamil are used together to control a supraventricular tachyarrhythmia, reduced dosage of each drug may be possible. Despite the possible negative inotropic effects of verapamil, digitoxin dosage probably will not have to be increased when a patient with congestive heart failure is given verapamil because increased digitoxin concentrations offset the possible negative inotropic effects of verapamil. Patients should be monitored for digitoxin toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75313,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75316,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Moderate",
      "effect": "Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.",
      "management_text": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75321,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Doxacurium",
      "severity": "Moderate",
      "effect": "Some calcium channel blockers may enhance the neuromuscular blocking properties of nondepolarizing muscle relaxants. The mechanism is not known, but may involve blockage of calcium channels on skeletal muscle. Data are available for verapamil, diltiazem, nicardipine, atracurium, vecuronium, and pancuronium.",
      "management_text": "Patients should be closely monitored for prolonged neuromuscular blockade. Reduced doses of muscle relaxants may be necessary. Profound neuromuscular blockade may be reversed by neostigmine or edrophonium.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75323,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Concurrent administration of verapamil may increase tricyclic antidepressant (TCA) serum concentrations. The mechanism appears to be inhibition of CYP450 metabolism. Pharmacologic and toxic effects of TCAs may be increased.",
      "management_text": "Close monitoring for clinical response and tolerance is recommended whenever verapamil is added to or discontinued from an antidepressant regimen. Patients should be advised to notify their physician if they experience excessive antidepressant effects such as dry mouth, blurry vision, irregular or fast heartbeat, constipation, urinary retention, dizziness, or orthostatic hypotension. Dose adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75325,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Moderate",
      "effect": "In the presence of verapamil, doxorubicin accumulates within cells, the intracellular distribution of doxorubicin shifts from cytoplasm to nucleus, and the formation of doxorubicin-related DNA strand breaks is increased. In the presence of verapamil, doxorubicin peak plasma levels, terminal half-life, and volume of distribution are significantly increased, whereas plasma clearance is significantly decreased. Although verapamil can be used to enhance the cytotoxicity of doxorubicin and has been used to overcome tumor cell resistance to doxorubicin, it can also increase the risk of side effects.",
      "management_text": "Close monitoring for doxorubicin toxicity (cardiac, hematologic, and hepatic) is recommended. A reduction in doxorubicin dosage may be necessary in some cases.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75326,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Moderate",
      "effect": "Coadministration of dronedarone and a calcium channel blocker (CCB) may result in increased plasma concentrations of both drugs. Dronedarone and most CCBs are substrates of CYP450 3A4. In addition, dronedarone and certain CCBs such as diltiazem and verapamil are also moderate inhibitors of the isoenzyme, thus competitive and noncompetitive metabolic inhibition may occur. Pharmacodynamically, CCBs with depressant effects on the sinus and AV nodes (particularly diltiazem, verapamil, and bepridil) could also potentiate dronedarone's effects on cardiac conduction.",
      "management_text": "Caution is advised if dronedarone is coadministered with a CCB. The dosage of the CCB should start low and increased only after ECG verification of good tolerability. Patients should be advised to promptly report potential symptoms of toxicity such as excessive fatigue; edema or swelling of the lower extremities; sudden, unexplained weight gain; fainting; difficulty breathing; chest pain or tightness; bradycardia; arrhythmia; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75329,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dutasteride",
      "severity": "Moderate",
      "effect": "Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the isoenzyme.",
      "management_text": "The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75331,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Duvelisib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when duvelisib is used with CYP450 3A4 inhibitors. Patients should be monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75332,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Echinacea",
      "severity": "Moderate",
      "effect": "Coadministration with echinacea may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to echinacea-mediated inhibition of CYP450 1A2.",
      "management_text": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever echinacea is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75333,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Edetate calcium disodium anhydrous",
      "severity": "Moderate",
      "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.",
      "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75334,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Empagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75339,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Enfortumab vedotin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin. Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.",
      "management_text": "Caution is advised when enfortumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycaemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75343,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.",
      "management_text": "Pharmacologic response to enzalutamide should be monitored more closely whenever a CYP450 2C8 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience increased side effects such as seizure, asthenia, fatigue, diarrhea, arthralgia, musculoskeletal pain, paresthesia, hot flushes, peripheral edema, headache, dizziness, insomnia, hematuria, anxiety, and hypertension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75345,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Epoprostenol",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75347,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ergometrine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.",
      "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75348,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ergotamine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.",
      "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75349,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ertugliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75352,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ethotoin",
      "severity": "Moderate",
      "effect": "Hydantoins may decrease verapamil serum concentrations and effectiveness. The mechanism is induction of CYP450 3A4 hepatic metabolism. Data are available for phenytoin only.",
      "management_text": "Monitored for reduced efficacy of verapamil is recommended. The dosage should be increased as appropriate. Patients should be advised to notify their physician if they experience a worsening of their symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75357,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75358,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Etravirine",
      "severity": "Moderate",
      "effect": "Coadministration of etravirine with a drug that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of etravirine and decreased plasma concentrations of the other drug. Etravirine itself is a substrate and inducer of CYP450 3A4. Theoretically, etravirine may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.",
      "management_text": "Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a drug that is an inhibitor of CYP450 3A4. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 3A4.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75360,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fenoldopam",
      "severity": "Moderate",
      "effect": "The use of fenoldopam with other hypotensive agents has not been studied. However, these combinations would theoretically increase the risk of severe symptomatic hypotension.",
      "management_text": "Caution is strongly advised during concurrent use. Inpatient monitoring of the heart rate and blood pressure is recommended. Sublingual nitroglycerin has been used safely with fenoldopam.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75363,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fesoterodine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.",
      "management_text": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary. Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75365,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.",
      "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75371,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75374,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Moderate",
      "effect": "Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.",
      "management_text": "Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75377,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fosaprepitant",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75378,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Moderate",
      "effect": "Hydantoins may decrease verapamil serum concentrations and effectiveness. The mechanism is induction of CYP450 3A4 hepatic metabolism. Data are available for phenytoin only.",
      "management_text": "Monitored for reduced efficacy of verapamil is recommended. The dosage should be increased as appropriate. Patients should be advised to notify their physician if they experience a worsening of their symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75380,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Moderate",
      "effect": "Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9. In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.",
      "management_text": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75381,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fostemsavir",
      "severity": "Moderate",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4, P-glycoprotein (P-gp), and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of temsavir, the active moiety of fostemsavir. Increased temsavir exposure may increase the risk of QT prolongation.",
      "management_text": "No dosage adjustments are recommended for fostemsavir when used with potent CYP450 3A4, P-gp, and/or BCRP inhibitors. It may be advisable to monitor patients for increased adverse effects such as QT prolongation during coadministration, particularly in the elderly and patients with risk factors for torsade de pointes.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75382,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gadopentetic acid",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75383,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gadoteric acid",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75384,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gadoxetic acid",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75385,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Moderate",
      "effect": "Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.",
      "management_text": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75386,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.",
      "management_text": "Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, pancreatitis, liver transaminase and bilirubin elevations, edema, infections and stomatitis, and the gilteritinib dosage adjusted as necessary in accordance with the product labeling.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75389,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Glasdegib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when glasdegib is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema and mucositis, and the glasdegib dosage adjusted as necessary in accordance with the product labeling.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75390,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Guanethidine",
      "severity": "Moderate",
      "effect": "The hypotensive effects of some calcium channel blockers and alpha-adrenergic blockers may be additive. The proposed mechanism is additive vasodilatory effects and inhibition of CYP450 hepatic metabolism of some alpha blockers by certain calcium channel blockers.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75395,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Halothane",
      "severity": "Moderate",
      "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.",
      "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75399,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Moderate",
      "effect": "Coadministration with moderate or strong inhibitors of CYP450 2C8 or CYP450 3A4 may increase the plasma concentration of hydroxychloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias.",
      "management_text": "Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate or strong CYP450 3A4 or 2C8 inhibitor is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75402,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Idarubicin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.",
      "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75404,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Moderate",
      "effect": "Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.",
      "management_text": "Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75405,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75406,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iloprost",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75407,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iodipamide",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75413,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iopanoic acid",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75414,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iopodic acid",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75415,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.",
      "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75416,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).",
      "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75418,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75419,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Isoflurane",
      "severity": "Moderate",
      "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.",
      "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75420,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Istradefylline",
      "severity": "Moderate",
      "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.",
      "management_text": "Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75421,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75663,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Voxelotor",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the systemic exposure (AUC) to voxelotor, which has been shown to be a substrate of this isoenzyme.",
      "management_text": "Caution is recommended if voxelotor is to be used with a CYP450 3A4 inhibitor. Dose adjustments may be necessary. Patients should be closely monitored for signs of voxelotor-related adverse effects, including headache, diarrhea, abdominal pain, nausea, and vomiting.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75684,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zonisamide",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zonisamide, which is metabolized by the isoenzyme. While clinical data are lacking, the possibility of prolonged and/or increased pharmacologic effects of zonisamide should be considered.",
      "management_text": "Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience symptoms such as severe drowsiness, confusion, loss of coordination, depression, aphasia, decreased sweating, fever, loss of seizure control, or slow pulse.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75689,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Grazoprevir",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.",
      "management_text": "Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 96731,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dalfopristin",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.",
      "management_text": "Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 109674,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fosnetupitant",
      "severity": "Moderate",
      "effect": "Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.",
      "management_text": "Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191187,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dihydrocodeine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 290049,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Butalbital",
      "severity": "Moderate",
      "effect": "Some barbiturates may significantly decrease serum verapamil concentrations and half-life, especially with oral dosage forms. The mechanism is induction of CYP450 3A4 first-pass metabolism of verapamil.",
      "management_text": "Close observation for reduced verapamil effect is recommended if these drugs must be used together. Dose adjustments may be required. Patients should also be monitored for verapamil toxicity after the barbiturate is discontinued.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11608,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Aldesleukin",
      "severity": "Moderate",
      "effect": "The concomitant administration of hypotensive agents may potentiate the hypotensive effects of aldesleukin. Life-threatening (grade 4) hypotension has been reported with aldesleukin alone.",
      "management_text": "Blood pressure should be monitored during concomitant administration. Aldesleukin doses should be held if systolic blood pressure falls to less than 90 mmHg.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13290,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Moderate",
      "effect": "The hypotensive effects of some calcium channel blockers and alpha-adrenergic blockers may be additive. The proposed mechanism is additive vasodilatory effects and inhibition of CYP450 hepatic metabolism of some alpha blockers by certain calcium channel blockers.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16461,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Concurrent administration of verapamil may increase tricyclic antidepressant (TCA) serum concentrations. The mechanism appears to be inhibition of CYP450 metabolism. Pharmacologic and toxic effects of TCAs may be increased.",
      "management_text": "Close monitoring for clinical response and tolerance is recommended whenever verapamil is added to or discontinued from an antidepressant regimen. Patients should be advised to notify their physician if they experience excessive antidepressant effects such as dry mouth, blurry vision, irregular or fast heartbeat, constipation, urinary retention, dizziness, or orthostatic hypotension. Dose adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22778,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23190,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with drugs that are inhibitors of CYP450 1A2 may increase the plasma concentrations of anagrelide, which is a substrate of the isoenzyme.",
      "management_text": "Clinicians should recognize the potential for interaction with drugs that inhibit CYP450 1A2 and monitor for evidence of anagrelide toxicities during coadministration. Since platelet reduction from anagrelide therapy is dose-related, thrombocytopenia may occur due to reduced clearance of anagrelide and may be a sign of overdosage. Patients should also be monitored for cardiovascular adverse effects such as tachycardia, palpitations, hypotension, edema, and congestive heart failure.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24987,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Betamethasone",
      "severity": "Moderate",
      "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.",
      "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 42138,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Moderate",
      "effect": "Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.",
      "management_text": "When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46473,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Brimonidine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia. The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.",
      "management_text": "Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs. Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 48677,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Buspirone",
      "severity": "Moderate",
      "effect": "The concomitant administration of verapamil may increase plasma buspirone concentrations. The proposed mechanism is inhibition of CYP3A4 mediated first pass metabolism by verapamil.",
      "management_text": "If this combination is to be used, the patient should be monitored carefully for signs of buspirone toxicity. Alternatively, use of a dihydropyridine calcium channel blocker or an anxiolytic which is not a substrate of CYP3A4 metabolism may be appropriate. Patients should be monitored for increased sedation and dizziness, and cautioned about possible impaired psychomotor performance.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51812,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cabergoline",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52984,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Moderate",
      "effect": "Coadministration with diltiazem may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by diltiazem.",
      "management_text": "Caution is advised if diltiazem must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever diltiazem is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58172,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cevimeline",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of cevimeline, which is metabolized by these isoenzymes.",
      "management_text": "Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience excessive adverse cholinergic effects of cevimeline such as nausea, vomiting, diarrhea, sweating, salivation, urinary frequency, visual disturbance, confusion, tremor, palpitations, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62010,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Chloroquine",
      "severity": "Moderate",
      "effect": "Coadministration with moderate or strong inhibitors of CYP450 2C8 or CYP450 3A4 may increase the plasma concentration of hydroxychloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias.",
      "management_text": "Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate or strong CYP450 3A4 or 2C8 inhibitor is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63281,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Moderate",
      "effect": "Coadministration with cimetidine may increase the plasma concentrations of calcium channel blockers that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by cimetidine.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if cimetidine is used in combination with calcium channel blockers that are metabolized by CYP450 3A4 such as diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nisoldipine, and verapamil. Dose reductions of 40% to 50% may be considered, if necessary. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis. Other H2-receptor antagonists may be safer alternatives, since they have not been shown to significantly affect CYP450 3A4 metabolism.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65818,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cisatracurium",
      "severity": "Moderate",
      "effect": "Some calcium channel blockers may enhance the neuromuscular blocking properties of nondepolarizing muscle relaxants. The mechanism is not known, but may involve blockage of calcium channels on skeletal muscle. Data are available for verapamil, diltiazem, nicardipine, atracurium, vecuronium, and pancuronium.",
      "management_text": "Patients should be closely monitored for prolonged neuromuscular blockade. Reduced doses of muscle relaxants may be necessary. Profound neuromuscular blockade may be reversed by neostigmine or edrophonium.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66501,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Moderate",
      "effect": "Coadministration of clonidine with agents known to affect sinus node function of AV nodal conduction may be associated with significantly reduced heart rate. The exact mechanism of interaction is unknown. However, these drugs individually have been associated with AV node dysfunction and may have additive effects during coadministration.",
      "management_text": "Heart rate and blood pressure should be closely monitored in patients receiving clonidine in combination with agents known to affect sinus node function of AV nodal conduction such as digitalis and certain calcium channel blockers.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 71604,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 72716,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Concurrent administration of verapamil may increase tricyclic antidepressant (TCA) serum concentrations. The mechanism appears to be inhibition of CYP450 metabolism. Pharmacologic and toxic effects of TCAs may be increased.",
      "management_text": "Close monitoring for clinical response and tolerance is recommended whenever verapamil is added to or discontinued from an antidepressant regimen. Patients should be advised to notify their physician if they experience excessive antidepressant effects such as dry mouth, blurry vision, irregular or fast heartbeat, constipation, urinary retention, dizziness, or orthostatic hypotension. Dose adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75268,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Butabarbital",
      "severity": "Moderate",
      "effect": "Some barbiturates may significantly decrease serum verapamil concentrations and half-life, especially with oral dosage forms. The mechanism is induction of CYP450 3A4 first-pass metabolism of verapamil.",
      "management_text": "Close observation for reduced verapamil effect is recommended if these drugs must be used together. Dose adjustments may be required. Patients should also be monitored for verapamil toxicity after the barbiturate is discontinued.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75276,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Calcium glucoheptonate",
      "severity": "Moderate",
      "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.",
      "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75281,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cerivastatin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.",
      "management_text": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75286,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75287,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clotrimazole",
      "severity": "Moderate",
      "effect": "Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75289,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Moderate",
      "effect": "Verapamil may inhibit the CYP450 3A4 hepatic metabolism of cyclosporine. Trough and steady state levels, and the risk of nephrotoxicity may be increased.",
      "management_text": "Cyclosporine levels and renal function should be monitored, and dosage should be adjusted as needed and appropriate during therapy. Other calcium channel blockers that have lesser effects on cyclosporine metabolism may be considered as alternatives (e.g., amlodipine, isradipine, nifedipine, nitrendipine).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75292,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.",
      "management_text": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of darifenacin such as severe abdominal pain or constipation for 3 or more days.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75298,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dexmedetomidine",
      "severity": "Moderate",
      "effect": "Dexmedetomidine has been associated with hypotensive and negative chronotropic effects. Coadministration with other agents causing these effects, especially vasodilators and alpha-2 agonists, may result in additive effects on blood pressure and heart rate.",
      "management_text": "Caution and monitoring of the patient's hemodynamic status are recommended during coadministration.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75310,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Diatrizoate",
      "severity": "Moderate",
      "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.",
      "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75311,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Moderate",
      "effect": "Verapamil increases digoxin levels significantly in most patients. Verapamil decreases renal and extrarenal clearance of digoxin. Serum digoxin levels may increase by 50% to 75% during the first week of concomitant verapamil therapy. Increases may be larger in patients with hepatic cirrhosis. Digoxin and verapamil have additive effects in slowing AV conduction.",
      "management_text": "If verapamil and digoxin are used together to control a supraventricular tachyarrhythmia, the dosage of each drug may have to be reduced. Despite the possible negative inotropic effects of verapamil, digoxin dosage probably will not have to be increased when a patient with congestive heart failure is given verapamil. Increased digoxin concentrations may offset the negative inotropic effects of verapamil. Patients should be closely monitored for clinical and laboratory evidence of digoxin safety and efficacy while taking verapamil and evaluated for underdigitalization when verapamil is discontinued. Patients should be advised to notify their physicians if they experience signs of toxicity such as nausea, anorexia, visual changes, slow pulse, or irregular heartbeats. Calcium channel blockers such as felodipine, or amlodipine, isradipine, and nicardipine appear to affect digoxin levels to a lesser extent or not at all and may be considered as alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75314,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dihydroergotamine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.",
      "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75315,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Moderate",
      "effect": "The hypotensive effects of some calcium channel blockers and alpha-adrenergic blockers may be additive. The proposed mechanism is additive vasodilatory effects and inhibition of CYP450 hepatic metabolism of some alpha blockers by certain calcium channel blockers.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75324,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dronabinol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75328,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of duloxetine, which is a substrate of the isoenzyme. Theoretically, high plasma levels of duloxetine may increase the risk of serious adverse effects such as hypertension, hypertensive crisis, increased heart rate, orthostatic hypotension, syncope, and serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.",
      "management_text": "Caution is advised if duloxetine is used in combination with CYP450 1A2 inhibitors. Pharmacologic response to duloxetine should be monitored more closely whenever a CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75330,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Moderate",
      "effect": "Coadministration with efavirenz may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by efavirenz.",
      "management_text": "Caution is advised if efavirenz must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever efavirenz is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75336,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Eletriptan",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eletriptan, which is primarily metabolized by the isoenzyme.",
      "management_text": "Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, nefazodone, delavirdine, most protease inhibitors, and ketolide and certain macrolide antibiotics. Patients should have vital signs monitored regularly and advised to notify their physician if they experience signs and symptoms of vasospasm such as numbness, tingling, or cyanosis in the extremities; muscle pains; weakness; or chest pain or tightness. Alternatively, other 5-HT1 receptor agonists that are not metabolized by CYP450 3A4 may be considered, such as frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75337,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Enflurane",
      "severity": "Moderate",
      "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.",
      "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75342,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Moderate",
      "effect": "Coadministration with an inhibitor of both CYP450 1A2 and 3A4 such as ciprofloxacin may significantly increase the plasma concentrations of erlotinib, which is a substrate of both isoenzymes.",
      "management_text": "Caution is advised if erlotinib must be used with inhibitors of both CYP450 1A2 and 3A4. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75351,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Eszopiclone",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-) enantiomer, eszopiclone. Zopiclone has been shown in vitro to be metabolized by CYP450 3A4 and CYP450 2C8, while eszopiclone is primarily metabolized by CYP450 3A4 and 2E1 via demethylation and oxidation.",
      "management_text": "Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected. Patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them, preferably at least 12 hours after administration of the hypnotic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75356,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Etomidate",
      "severity": "Moderate",
      "effect": "Verapamil may enhance the anesthetic effect of etomidate. Prolonged anesthesia and profound respiratory depression could result. The mechanism is unknown.",
      "management_text": "The clinician should be aware of the risk of respiratory arrest and the need for close monitoring and ventilatory support.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75359,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75364,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Moderate",
      "effect": "Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75370,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Coadministration of fluoxetine with calcium channel blockers may increase their plasma concentrations and the risk of side effects. The mechanism is reduced clearance of the calcium channel blocker due to inhibition of CYP450 3A4-mediated metabolism by fluoxetine. Reports exist for nifedipine, nimodipine, and verapamil. Theoretically, the interaction may also occur with other calcium channel blockers that are CYP450 3A4 substrates.",
      "management_text": "Monitoring of clinical response and tolerance, including blood pressure, is recommended if fluoxetine is used in combination with calcium channel blockers that are metabolized by CYP450 3A4. Dose reductions may be considered, if necessary. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75372,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75373,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Coadministration with fluvoxamine may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to competitive inhibition of CYP450 3A4 activity by fluvoxamine.",
      "management_text": "Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluvoxamine is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75376,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of gefitinib (250 mg single dose) with the potent inhibitor itraconazole (200 mg once a day for 12 days) increased the mean gefitinib systemic exposure (AUC) by 88% in healthy male volunteers.",
      "management_text": "Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience possible symptoms of gefitinib toxicity such as severe diarrhea, nausea, dyspnea, cough, and fever.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75388,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Grepafloxacin",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.",
      "management_text": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75392,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Guanabenz",
      "severity": "Moderate",
      "effect": "The hypotensive effects of some calcium channel blockers and alpha-adrenergic blockers may be additive. The proposed mechanism is additive vasodilatory effects and inhibition of CYP450 hepatic metabolism of some alpha blockers by certain calcium channel blockers.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75393,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Guanadrel",
      "severity": "Moderate",
      "effect": "The hypotensive effects of some calcium channel blockers and alpha-adrenergic blockers may be additive. The proposed mechanism is additive vasodilatory effects and inhibition of CYP450 hepatic metabolism of some alpha blockers by certain calcium channel blockers.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75394,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75398,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75401,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Moderate",
      "effect": "Imatinib is a substrate of the CYP450 3A4 isoenzyme as well as a potent competitive inhibitor of the CYP450 2C9, 2D6 and 3A4 isoenzymes. Some drugs that are known inhibitors of CYP450 3A4 are also metabolized by one or more of the isoenzymes inhibited by imatinib. Theoretically, coadministration of imatinib with those drugs may result in mutually elevated plasma drug concentrations due to competitive and noncompetitive inhibition of CYP450 activities.",
      "management_text": "The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin. In addition, clinical and laboratory monitoring for potentially increased pharmacologic effects of coadministered medications is recommended, especially those with a narrow therapeutic range.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75408,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Concurrent administration of verapamil may increase tricyclic antidepressant (TCA) serum concentrations. The mechanism appears to be inhibition of CYP450 metabolism. Pharmacologic and toxic effects of TCAs may be increased.",
      "management_text": "Close monitoring for clinical response and tolerance is recommended whenever verapamil is added to or discontinued from an antidepressant regimen. Patients should be advised to notify their physician if they experience excessive antidepressant effects such as dry mouth, blurry vision, irregular or fast heartbeat, constipation, urinary retention, dizziness, or orthostatic hypotension. Dose adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75409,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Moderate",
      "effect": "Coadministration with indinavir may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves indinavir inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most calcium channel blockers.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with indinavir. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75411,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75412,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75559,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV). The possibility of prolonged and/or increased pharmacologic effects of venlafaxine should be considered. Although venlafaxine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of venlafaxine. The interaction may be of greater concern in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent).",
      "management_text": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75678,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Moderate",
      "effect": "Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.",
      "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75683,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75687,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zolpidem, which is partially metabolized by the isoenzyme.",
      "management_text": "Caution is advised when zolpidem is used with CYP450 3A4 inhibitors. Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them, and to notify their physician if they experience excessive somnolence or dizziness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75688,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iobenguane (I-123)",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that block norepinephrine uptake or deplete norepinephrine stores may decrease iobenguane I-123 uptake in neuroendocrine tumors and lead to false-negative imaging results.",
      "management_text": "When medically feasible, any drug that blocks norepinephrine uptake or deplete norepinephrine stores should be discontinued for at least five biological half-lives before iobenguane I-123 administration.  Patients should be monitored for the occurrence of clinically significant withdrawal symptoms, especially patients with elevated levels of circulating catecholamines and their metabolites.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 241315,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "There is clinical evidence that eslicarbazepine acetate can prolong the PR interval of the electrocardiogram (ECG) in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, lopinavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular (AV) block.",
      "management_text": "Caution is advised if eslicarbazepine is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block; second-degree or higher AV block; sick sinus syndrome without pacemaker), or a history of syncope, arrhythmia or severe cardiac disease such as myocardial ischemia or heart failure.  Patients should be advised to notify their doctor if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 252371,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dexmethylphenidate",
      "severity": "Moderate",
      "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.",
      "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 261187,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Drospirenone",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.",
      "management_text": "Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 261188,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Codeine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 289222,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Diphenhydramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 289244,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 291647,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Chloral hydrate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 302497,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Chlorphenesin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 302498,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Chlorzoxazone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 302499,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 302500,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 302501,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 302506,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dolutegravir",
      "severity": "Minor",
      "effect": "Theoretically, coadministration with inhibitors of UGT1A or CYP450 3A4 isoenzymes may increase the plasma concentrations of dolutegravir, which is primarily metabolized by UGT1A1 with some contribution from CYP450 3A4. Because safety data regarding increased dolutegravir exposures are limited, caution may be advisable if dolutegravir is used in combination with both a UGT1A1 inhibitor and a CYP450 3A4 inhibitor.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 197,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Almotriptan",
      "severity": "Minor",
      "effect": "According to the product labeling, coadministration of almotriptan (12.5 mg single oral dose) with verapamil (120 mg sustained-release tablets twice a day for 7 days) in healthy volunteers resulted in a 24% increase in almotriptan peak plasma concentration (Cmax) and a 20% increase in systemic exposure (AUC). The proposed mechanism is verapamil inhibition of almotriptan metabolism via CYP450 3A4.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 17736,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cannabidiol",
      "severity": "Minor",
      "effect": "Cannabidiol is a substrate for CYP450 3A4 and CYP450 2C19. Cannabidiol is metabolized in the liver and the gut (primarily in the liver) by CYP450 2C19 and CYP450 3A4 enzymes, and UGT1A7, UGT1A9, and UGT2B7 isoforms.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 55257,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Minor",
      "effect": "Calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors may have additive hypotensive effects. While these drugs are often safely used together, careful monitoring of the systemic blood pressure is recommended during coadministration, especially during the first one to three weeks of therapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 56110,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Darolutamide",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75299,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Doravirine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75322,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Eribulin",
      "severity": "Minor",
      "effect": "The concomitant use of eribulin with drugs that inhibit hepatic transport proteins (e.g., organic anion-transporting proteins or multidrug resistant proteins) may theoretically increase its plasma concentrations. Up to 70% of an eribulin dose is eliminated through biliary excretion. Clinical data have not been reported.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75350,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75354,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Minor",
      "effect": "Coadministration of fedratinib with moderate CYP450 3A4 inhibitors may increase the plasma concentrations and the risk of adverse effects of fedratinib, which is a substrate of the isoenzyme. However, clinical data are not available. Until further information is available, caution and monitoring for adverse effects including anemia, thrombocytopenia, gastrointestinal toxicity, and hepatic and pancreatic enzyme elevations is advised if fedratinib is used with moderate CYP450 3A4 inhibitors.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75362,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fidaxomicin",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75366,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Garlic",
      "severity": "Minor",
      "effect": "Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75387,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Minor",
      "effect": "The concomitant use of verapamil therapy may modestly increase serum levels of glyburide; however, glucose lowering effects are not altered. The mechanism has not been determined.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75391,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Diamorphine",
      "severity": "Minor",
      "effect": "One study of polysubstance abusers has suggested that verapamil may attenuate the euphoragenic effects of morphine and potentiate the analgesic effects. The clinical implications of this interaction for patients with pain are unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75400,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Indacaterol",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75410,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zileuton",
      "severity": "Minor",
      "effect": "Zileuton is believed to be a weak inhibitor of cytochrome P450 3A4 enzymes, of which calcium channel blockers are a known substrate. Although no studies have been conducted to verify or quantify the interaction, caution is recommended when using this combination until further data is available.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75686,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bexarotene",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may theoretically increase the plasma concentrations of bexarotene. In vitro studies suggest that bexarotene is metabolized by CYP450 3A4. However, concomitant administration with multiple doses of ketoconazole, a potent CYP450 3A4 inhibitor, did not alter bexarotene plasma concentrations, which would imply that bexarotene elimination is not substantially dependent on CYP450 3A4 metabolism in vivo. Conversely, bexarotene appears to be an inducer of CYP450 3A4 and may reduce the plasma concentrations of CYP450 3A4 inhibitors that are also substrates of the isoenzyme, such as azole antifungals, macrolides, some calcium channel blockers, mifepristone, and nefazodone.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 43397,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Minor",
      "effect": "Diclofenac reduces serum verapamil concentrations. The mechanism is unknown. However, patients on concomitant therapy should be monitored for reduced verapamil efficacy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 54190,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 67262,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Minor",
      "effect": "Calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors may have additive hypotensive effects. While these drugs are often safely used together, careful monitoring of the systemic blood pressure is recommended during coadministration, especially during the first one to three weeks of therapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75340,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Minor",
      "effect": "Calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors may have additive hypotensive effects. While these drugs are often safely used together, careful monitoring of the systemic blood pressure is recommended during coadministration, especially during the first one to three weeks of therapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75379,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Minor",
      "effect": "In vitro tests have shown that verapamil displaces vincristine from protein-binding sites--particularly alpha(1) -acid glycoprotein, or AGP. The clinical significance is unknown. If verapamil and vincristine are used concomitantly, close neurological observation is advised.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75681,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214045,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214047,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ibandronate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214050,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214054,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214058,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gentamicin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214060,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dicyclomine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214061,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214062,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214065,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cefaclor",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214066,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214071,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214073,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bimatoprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214075,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214080,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214081,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fulvestrant",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214084,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214085,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Isoniazid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214086,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214089,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zaleplon",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214090,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Desloratadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214092,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214094,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dipyridamole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214095,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Formoterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214096,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Exemestane",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214097,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214098,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214099,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cromoglicic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214100,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214101,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cinacalcet",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214103,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214104,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214106,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214107,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214109,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gatifloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214111,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214114,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214115,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fludarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214116,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fluvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214120,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Capecitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214123,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cefuroxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214125,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zopiclone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214132,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214134,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214136,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214138,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214140,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ambrisentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214145,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214146,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Epinephrine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214238,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amphotericin B",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214744,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alprostadil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217599,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217946,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218279,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221478,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amantadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222250,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alosetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224169,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amoxicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227992,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229747,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Anastrozole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233653,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Galactose",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236674,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bupivacaine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200311,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204298,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212877,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Adenosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213286,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213952,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Eptifibatide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213953,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cyanocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213954,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213955,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213956,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Flunisolide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213959,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amphetamine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213960,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213962,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Adapalene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213966,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213970,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213974,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Chlorthalidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213982,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zolmitriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213984,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213986,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213992,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zoledronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213994,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Famciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213999,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214000,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ceftazidime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214001,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214003,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214005,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214010,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cefotaxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214011,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Flutamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214012,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Dextromethorphan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214014,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214015,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214018,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cefdinir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214020,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214021,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214022,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Zafirlukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214024,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214027,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214029,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214034,
      "ingredient1": "Verapamil"
    },
    {
      "ingredient2": "Deferiprone",
      "severity": "Moderate",
      "effect": "Coadministration of deferiprone with uridine diphosphate glucuronosyltransferase (UGT) 1A6 inhibitors may increase the plasma concentrations of deferiprone, which is metabolized by the enzyme.",
      "management_text": "The use of deferiprone with UGT1A6 inhibitors should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81881,
      "ingredient1": "Milk thistle"
    },
    {
      "ingredient2": "Raloxifene",
      "severity": "Moderate",
      "effect": "Coadministration with milk thistle constituents silibinin and silymarin may increase raloxifene systemic exposure (AUC). The mechanism involves inhibition of raloxifene glucuronidation in the intestines by milk thistle flavonolignans silybin A and silybin B.",
      "management_text": "Patients should be monitored for adverse effects from raloxifene if coadministered with milk thistle or its constituents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 109695,
      "ingredient1": "Milk thistle"
    },
    {
      "ingredient2": "Simeprevir",
      "severity": "Moderate",
      "effect": "Coadministration with milk thistle may increase the plasma concentrations of simeprevir. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism by milk thistle.",
      "management_text": "The use of simeprevir with products containing milk thistle should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166069,
      "ingredient1": "Milk thistle"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Minor",
      "effect": "Milk thistle does not appear to substantially alter the pharmacokinetics of indinavir. In general, patients should consult a healthcare provider before taking any herbal or alternative medicine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 188421,
      "ingredient1": "Milk thistle"
    },
    {
      "ingredient2": "Isometheptene",
      "severity": "Moderate",
      "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.",
      "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5545,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Inotuzumab ozogamicin",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115339,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115784,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Ivabradine",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 121293,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Insulin human",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 252990,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24797,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115568,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116071,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Insulin glargine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116287,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116557,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.",
      "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119791,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Isoprenaline",
      "severity": "Moderate",
      "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.",
      "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 120134,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Insulin lispro",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186774,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.",
      "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188138,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188238,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Isoetharine",
      "severity": "Moderate",
      "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.",
      "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188244,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 97076,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 119524,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Istradefylline",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 120877,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 121026,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 187989,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 188239,
      "ingredient1": "Indacaterol"
    },
    {
      "ingredient2": "Homatropine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 27172,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50424,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Hyoscyamine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25338,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Guanidine",
      "severity": "Moderate",
      "effect": "Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may antagonize the effects of cholinergic skeletal muscle stimulants (e.g., ambenonium, edrophonium, guanidine, neostigmine, pyridostigmine). Although this interaction may be desirable in some situations, such as when atropine is used to treat excessive muscarinic side effects and cholinergic crisis induced by anticholinesterase overdose, unintentional or indiscriminate use of anticholinergic agents in the treatment of myasthenia gravis may exacerbate symptoms.",
      "management_text": "Agents with potent anticholinergic activity should preferably be avoided in patients receiving cholinergic skeletal muscle stimulants. If concurrent use is necessary, patients treated for myasthenia gravis should be monitored for potential exacerbation of symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50420,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50421,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50422,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50423,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50425,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Ipratropium",
      "severity": "Moderate",
      "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.",
      "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50426,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Isoflurophate (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50428,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186029,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Minor",
      "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 17101,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Minor",
      "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 119772,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Hydroflumethiazide",
      "severity": "Minor",
      "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 186028,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Minor",
      "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 186030,
      "ingredient1": "glycopyrronium"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Major",
      "effect": "The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with other agents that can reduce the seizure threshold, including antidepressants, CNS stimulants, acetylcholinesterase inhibitors, phenothiazines, and dopaminergic blocking agents such as neuroleptics and metoclopramide. Coadministration with bupropion may increase the plasma concentrations of drugs that are metabolized by CYP450 2D6, including many antidepressants, neuroleptics, CNS stimulants (e.g., amphetamines), metoclopramide, and some acetylcholinesterase inhibitors (e.g., donepezil, galantamine). The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by bupropion and its metabolite, hydroxybupropion.",
      "management_text": "Extreme caution is advised if bupropion is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin). Bupropion as well as concomitant medications should be initiated at the lower end of the dosage range and titrated gradually as needed and as tolerated. The maximum recommended dosage for the specific bupropion formulation should not be exceeded.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 28458,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 120747,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 147859,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Major",
      "effect": "The risk of seizures may be increased during coadministration of tramadol with any substance that can reduce the seizure threshold, such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with tramadol.",
      "management_text": "Caution is advised if tramadol is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 6058,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Amifampridine",
      "severity": "Moderate",
      "effect": "The use of amifampridine is associated with a dose-related risk of seizures, and the risk may be further increased when coadministered with other drugs that can reduce the seizure threshold. Seizures have occurred in patients without a history of seizures taking amifampridine at recommended dosages and at various times after initiation of treatment.",
      "management_text": "Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin). Consider discontinuation or dose reduction of amifampridine in patients who experience a seizure during treatment. Use of amifampridine is contraindicated in patients with a history of seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20630,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Picosulfuric acid",
      "severity": "Moderate",
      "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.",
      "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 68812,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Polyethylene glycol (3350 with electrolytes)",
      "severity": "Moderate",
      "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.",
      "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 69174,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Sodium sulfate",
      "severity": "Moderate",
      "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.",
      "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111874,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Iodide I-131",
      "severity": "Moderate",
      "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.",
      "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 122296,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "The risk of seizures may be increased during coadministration of fluphenazine with any substance that can reduce the seizure threshold, such as aminophylline, antidepressants, antipsychotics, opioids, carbapenems, etc. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with fluphenazine.",
      "management_text": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183617,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Ginkgo biloba",
      "severity": "Moderate",
      "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191408,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Iodide I-123",
      "severity": "Moderate",
      "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.",
      "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192021,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Sodium phosphate, monobasic",
      "severity": "Moderate",
      "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.",
      "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 294818,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "A case report has suggested that piperazine may provoke seizures in patients being treated with chlorpromazine. The mechanism is unknown. Controlled clinical studies are needed to definitively document this interaction.",
      "management_text": "The patient should be closely observed for seizure activity and if a seizure occurs, this interaction may be suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190061,
      "ingredient1": "piperazine"
    },
    {
      "ingredient2": "Abatacept",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 916,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Abemaciclib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 1185,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 1459,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Paclitaxel",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 1927,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Acalabrutinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 2882,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Trastuzumab emtansine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 9856,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Afatinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10581,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Alectinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 13339,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18335,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ambrisentan",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 20436,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21596,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 28343,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Asparaginase Erwinia chrysanthemi",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33616,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Atezolizumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 35418,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Atovaquone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 35960,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Avapritinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 36632,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Axitinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 36902,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Phenazopyridine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 37998,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Baricitinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 38791,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39260,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Belantamab mafodotin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40120,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Belatacept",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40187,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Belimumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40248,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bendamustine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40697,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 43535,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Binimetinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 43936,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Blinatumomab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 45535,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 46637,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Brentuximab vedotin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 47096,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Brigatinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 48171,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Brodalumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 49423,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 50165,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Cabazitaxel",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 52743,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Calaspargase pegol",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 53496,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Canakinumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 54586,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Cannabidiol",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 55005,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Capecitabine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 55338,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Capmatinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 55614,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 55948,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Carfilzomib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 58278,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61236,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Certolizumab pegol",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61653,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Chenodeoxycholic acid",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 62038,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 64916,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 67882,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Cobimetinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 73020,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Corticotropin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 74734,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tetracosactide",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75151,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75872,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Danazol",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 78420,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 78588,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Daratumumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 79261,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Darunavir",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 79854,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 80227,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Decitabine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81364,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81559,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Deferiprone",
      "severity": "Major",
      "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.",
      "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81859,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 82208,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Prasterone enantate",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 82552,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dimethyl fumarate",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 87192,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dinutuximab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 87369,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Diroximel fumarate",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 88035,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 89474,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 92563,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dupilumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 94042,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Durvalumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 94089,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Duvelisib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 94477,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Elagolix",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 96441,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 97095,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Eltrombopag",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 97675,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Enfortumab vedotin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 99589,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Varicella Zoster Vaccine (Recombinant)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 102051,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Phenyl salicylate",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 102509,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Methyltestosterone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 102667,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Olaratumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 104924,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Onasemnogene abeparvovec",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 105774,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Oxymetholone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106690,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Risankizumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 110138,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Rotavirus vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 110695,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tolvaptan",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 111015,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tildrakizumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 113705,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Vedolizumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 114969,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Inotersen",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 115197,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Inotuzumab ozogamicin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 115355,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Iobenguane (I-131)",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 118705,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ipilimumab",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 118977,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Isatuximab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 119395,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 121039,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ofatumumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 122791,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Mitoxantrone",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 123477,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Mogamulizumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 124103,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Monomethyl fumarate",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 124425,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Aurothioglucose",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128446,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Axicabtagene ciloleucel",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128447,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bacillus calmette-guerin substrain tice live antigen",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128448,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bedaquiline",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128449,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Belinostat",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128450,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Brexucabtagene autoleucel",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128453,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Copanlisib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128462,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Elotuzumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128471,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128472,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Eribulin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128474,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Everolimus",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128483,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Trastuzumab deruxtecan",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128484,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Febuxostat",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128485,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128486,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Fenofibric acid",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128488,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive agents such as fingolimod may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant immunosuppressive therapy. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. No specific data are available regarding use in combination with fingolimod, an agent that causes reversible sequestration of lymphocytes in lymphoid tissues. The concomitant or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Elevated liver transaminases, hepatitis, jaundice/cholestasis, hepatic failure, and acute hepatic necrosis have been reported with leflunomide. Liver enzyme elevations were generally mild (2-fold ULN or less) and resolved while continuing treatment. Marked elevations (greater than 3-fold ULN) occurred infrequently and reversed with dose reduction or discontinuation of treatment. However, fatalities associated with severe liver injury have also been reported rarely.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. If evidence of serious hepatotoxicity (i.e., ALT elevation greater than 3-fold ULN or persistent elevations between 2- and 3-fold ULN despite dose reduction), infection, or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Similarly, recent complete blood count and transaminase and bilirubin levels (i.e., within last 6 months) should be available before initiating treatment with fingolimod. If a serious infection or significant liver injury develops, treatment should be suspended and the benefits and risks reassessed prior to restarting treatment. Because fingolimod remains in the blood for up to two months after the last dose, continued monitoring is recommended throughout this period. Patients should be advised to seek medical attention if they develop an infection or experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, light colored stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128490,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Fluoxymesterone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128496,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128501,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128502,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128507,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Givosiran",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128508,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Sodium aurothiomalate",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128512,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Golimumab",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128513,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Guselkumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128514,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128518,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ibrutinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128521,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Idarubicin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128522,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128523,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128524,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Inebilizumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128527,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Levofloxacin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128543,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Lisocabtagene maraleucel",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128545,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Lomitapide",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128546,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Lomustine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128547,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Lurbinectedin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128550,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Lutetium Lu 177 dotatate",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128551,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Macitentan",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128553,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Maraviroc",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128554,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Measles virus vaccine live attenuated",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128555,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Midostaurin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128567,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Milnacipran",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128568,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Mipomersen",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128569,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Mumps virus strain B level jeryl lynn live antigen",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128571,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Naxitamab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128575,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Nefazodone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128576,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Nelarabine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128577,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Nicotinamide",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128579,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Nilotinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128580,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Nintedanib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128582,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Niraparib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128583,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Obinutuzumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128585,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ocrelizumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128586,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Olaparib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128587,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Omacetaxine mepesuccinate",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128588,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Osimertinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128590,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ozanimod",
      "severity": "Major",
      "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.",
      "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128592,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Palbociclib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128594,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Panobinostat",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128595,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pasireotide",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128596,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pazopanib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128597,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Peginterferon beta-1a",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128601,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pemoline",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128603,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pexidartinib",
      "severity": "Major",
      "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.",
      "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128606,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pirfenidone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128609,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pitavastatin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128611,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Plicamycin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128612,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Polatuzumab vedotin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128613,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pomalidomide",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128614,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ponatinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128615,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128616,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pralatrexate",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128617,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Pralsetinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128618,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Procarbazine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128622,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Regorafenib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128627,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ribociclib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128629,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Rilonacept",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128631,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Rilpivirine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128632,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Romidepsin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128635,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Rosuvastatin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. Coadministration with teriflunomide may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and 1B3 and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vivo data, is decreased clearance due to teriflunomide-mediated inhibition of OATP 1B1/1B3 or BCRP transport proteins.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents or are receiving drugs that are substrates of OATP 1B1/1B3 and/or BCRP, such as rosuvastatin. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. If concomitant administration is required, the dose of rosuvastatin should not exceed 10 mg once daily. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever leflunomide or teriflunomide is added to or withdrawn from therapy with rosuvastatin.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128637,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Rubella virus vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128638,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Rucaparib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128639,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ruxolitinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128640,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Sacituzumab govitecan",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128641,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Salsalate",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128642,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Sarilumab",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128643,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Satralizumab",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128645,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Secukinumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128646,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Selinexor",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128647,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128648,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Siltuximab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128649,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Siponimod",
      "severity": "Major",
      "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.",
      "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128651,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Smallpox (Vaccinia) Vaccine, Live",
      "severity": "Major",
      "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128654,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Stanozolol",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128657,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Sunitinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128661,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tafasitamab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128664,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tagraxofusp",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128665,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Talazoparib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128666,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Talimogene laherparepvec",
      "severity": "Major",
      "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128667,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Temsirolimus",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128671,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Teriflunomide",
      "severity": "Major",
      "effect": "Teriflunomide is the active metabolite of leflunomide and has a similar toxicity profile as the parent drug.",
      "management_text": "Concomitant use of leflunomide and teriflunomide is considered contraindicated due to the potential for increased toxicities such as peripheral neuropathy, serious liver injury, and bone marrow suppression.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128674,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Thiotepa",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128678,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tisagenlecleucel",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128681,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tocilizumab",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128683,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tofacitinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128684,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Trabectedin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128692,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Trimetrexate",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128696,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Troleandomycin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128698,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Tucatinib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128701,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Typhoid vaccine (live)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128703,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Upadacitinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128704,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ustekinumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128706,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Vemurafenib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128709,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Venetoclax",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128710,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Yellow Fever Vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128717,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Zanubrutinib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128720,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Aflibercept",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 128724,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Melphalan flufenamide",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.  Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.  Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.  If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 252821,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Promazine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.  Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.  Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.  If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 252839,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Trifluridine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.  Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.  Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.  If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 301513,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Zidovudine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 354,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Isotretinoin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 2119,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Acarbose",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 3165,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Acetaminophen",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 4500,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Acitretin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 7060,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Adalimumab",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 9258,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10311,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 11282,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 12634,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Aldesleukin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 13084,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Alefacept",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 13525,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Alemtuzumab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 13811,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Altretamine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 19790,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Diclofenac (topical)",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 20156,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Aminosalicylic acid",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21300,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Atorvastatin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23219,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Benazepril",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23346,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23546,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Clavulanic acid",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 24313,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Anakinra",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 25128,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Testosterone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 25551,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26663,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Antithymocyte immunoglobulin (rabbit)",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 27007,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 30989,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Asparaginase Escherichia coli",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33295,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33916,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Atomoxetine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 35563,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Auranofin",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 36239,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Azacitidine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 37138,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Azathioprine",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 37301,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Azithromycin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 37822,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Basiliximab",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 38969,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Betamethasone",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 41948,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bexarotene",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 43187,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Emtricitabine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 43795,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bleomycin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 45408,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 46005,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 46303,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Busulfan",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 51900,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 56419,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 57543,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Carmustine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 59119,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Chlorambucil",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 62125,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Chlorzoxazone",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 64340,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 66625,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Cladribine",
      "severity": "Major",
      "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 67529,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Clofarabine",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 70066,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Major",
      "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.",
      "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 72358,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 76744,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Major",
      "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. There have also been rare reports of pancytopenia, agranulocytosis, and thrombocytopenia in patients receiving leflunomide alone.",
      "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment with leflunomide should be stopped and washout procedure administered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 77039,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Dactinomycin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 78136,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Daunorubicin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 80639,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Oxaprozin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81190,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Denileukin diftitox",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 83053,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 86299,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Disulfiram",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 89047,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 89206,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Major",
      "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.",
      "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 91964,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 93708,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Minocycline",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 94759,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 95603,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 96009,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 98663,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Lisinopril",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 100692,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 100911,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Methyldopa",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 102312,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Moexipril",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 102826,
      "ingredient1": "Leflunomide"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.",
      "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 103201,
      "ingredient1": "Leflunomide"
    }
  ]
}